

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/116495>

Please be advised that this information was generated on 2021-04-17 and may be subject to change.



OPEN ACCESS



Open Access
Scan to access more
free content

ORIGINAL ARTICLE

Exome sequencing identifies *DYNC2H1* mutations as a common cause of asphyxiating thoracic dystrophy (Jeune syndrome) without major polydactyly, renal or retinal involvement

Miriam Schmidts,¹ Heleen H Arts,^{2,3,4} Ernie M H F Bongers,^{2,3,4} Zhimin Yap,¹ Machteld M Oud,^{2,3,4} Dinu Antony,¹ Lonneke Duijkers,^{3,5} Richard D Emes,⁶ Jim Stalker,⁷ Jan-Bart L Yntema,⁸ Vincent Plagnol,⁹ Alexander Hoischen,^{2,3,4} Christian Gilissen,^{2,3,4} Elisabeth Forsythe,¹ Ekkehart Lausch,¹⁰ Joris A Veltman,^{2,3,4} Nel Roeleveld,^{4,11,12} Andrea Superti-Furga,¹³ Anna Kutkowska-Kazmierczak,¹⁴ Erik-Jan Kamsteeg,^{2,3,4} Nursel Elçioğlu,¹⁵ Merel C van Maarle,¹⁶ Luitgard M Graul-Neumann,¹⁷ Koenraad Devriendt,¹⁸ Sarah F Smithson,¹⁹ Diana Wellesley,²⁰ Nienke E Verbeek,²¹ Raoul C M Hennekam,²² Hulya Kayserili,²³ Peter J Scambler,¹ Philip L Beales,¹ UK10K,²⁴ Nine VAM Knoers,²¹ Ronald Roepman,^{2,3,4} Hannah M Mitchison¹

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/jmedgenet-2012-101284>).

For numbered affiliations see end of article.

Correspondence to

Dr Hannah M Mitchison, Molecular Medicine Unit, Birth Defects Research Centre, University College London (UCL) Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK; h.mitchison@ucl.ac.uk and Heleen H Arts, Department of Human Genetics (855), Radboud University Nijmegen Medical Centre, Geert Grooteplein Zuid 10, Nijmegen 6525 GA, The Netherlands; h.arts@gen.umcn.nl

MS, HHA, NVAMK, RR and HMM contributed equally.

Received 7 September 2012
Accepted 21 January 2013
Published Online First
1 March 2013



► <http://dx.doi.org/10.1136/jmedgenet-2012-101284>

To cite: Schmidts M, Arts HH, Bongers EMHF, et al. *J Med Genet* 2013;**50**:309–323.

ABSTRACT

Background Jeune asphyxiating thoracic dystrophy (JATD) is a rare, often lethal, recessively inherited chondrodysplasia characterised by shortened ribs and long bones, sometimes accompanied by polydactyly, and renal, liver and retinal disease. Mutations in intraflagellar transport (IFT) genes cause JATD, including the IFT dynein-2 motor subunit gene *DYNC2H1*. Genetic heterogeneity and the large *DYNC2H1* gene size have hindered JATD genetic diagnosis.

Aims and methods To determine the contribution to JATD we screened *DYNC2H1* in 71 JATD patients JATD patients combining SNP mapping, Sanger sequencing and exome sequencing.

Results and conclusions We detected 34 *DYNC2H1* mutations in 29/71 (41%) patients from 19/57 families (33%), showing it as a major cause of JATD especially in Northern European patients. This included 13 early protein termination mutations (nonsense/frameshift, deletion, splice site) but no patients carried these in combination, suggesting the human phenotype is at least partly hypomorphic. In addition, 21 missense mutations were distributed across *DYNC2H1* and these showed some clustering to functional domains, especially the ATP motor domain. *DYNC2H1* patients largely lacked significant extra-skeletal involvement, demonstrating an important genotype–phenotype correlation in JATD. Significant variability exists in the course and severity of the thoracic phenotype, both between affected siblings with identical *DYNC2H1* alleles and among individuals with different alleles, which suggests the *DYNC2H1* phenotype might be subject to modifier alleles, non-genetic or epigenetic factors. Assessment of fibroblasts from patients showed accumulation of anterograde IFT proteins in the ciliary tips, confirming defects similar to patients with other retrograde IFT machinery mutations, which may be of undervalued potential for diagnostic purposes.

INTRODUCTION

Asphyxiating thoracic dystrophy or Jeune syndrome (Jeune asphyxiating thoracic dystrophy (JATD); MIM 208500), first described in 1955,¹ is a rare genetically heterogeneous disorder characterised by skeletal anomalies, primarily shortened ribs and limbs, brachydactyly and polydactyly. Constriction of the thoracic cage is associated with recurrent respiratory infections in particular in neonates and infants, and in 60% of cases with lethal respiratory distress.² Up to 30% of JATD patients also develop end stage renal disease,³ with hepatic fibrosis and retinal involvement reported less frequently.^{4–5} JATD is a member of the family of skeletal ‘ciliopathies’, disorders associated with dysfunction of primary cilia, classified as one of the six short-rib polydactyly syndrome (SRPS) disorders.^{6–7} JATD along with Ellis-van Creveld syndrome is an SRPS compatible with life, rather than one of the four lethal SRPS subtypes (SRPS I–IV).⁷ In addition, JATD is both phenotypically as well as genetically related to Sensenbrenner syndrome (Cranioectodermal dysplasia; MIM 218330)⁸ and Mainzer-Saldino syndrome (Conorenal syndrome; MIM 266920).⁹

Mutations in several different genes cause JATD. These genes, *IFT80*,¹⁰ *TTC21B/IFT139*,¹¹ *IFT140*,^{9–12} *WDR19/IFT144*⁸ and *DYNC2H1*¹³ all encode proteins that participate in ciliary intraflagellar transport (IFT), an evolutionarily conserved process which is essential for ciliogenesis and governs a variety of important cell signalling events that are key to normal human development.^{14–15} In IFT, two protein complexes IFT-A and IFT-B are bidirectionally transported in cilia by molecular motors, along with essential ciliary cargos.^{16–17} The IFT80 protein is part of the IFT-B particle that consists of at least 14 proteins, which in association with kinesin-2 motors drives anterograde transport from the ciliary base to the tip while IFT139,

IFT140 and IFT144 are all part of the IFT-A particle that consists of six proteins and in association with the cytoplasmic IFT dynein-2/1b motor drives retrograde transport from the ciliary tip to the base.^{17–19} The other three IFT-A members, *IFT122*, *IFT43* and *WDR35*, are mutated in Sensenbrenner syndrome.^{20–22} Similarly, *IFT144* and *IFT80* are also mutated in overlapping milder syndromes and in more severe type III short-rib polydactyly.^{8 23} *IFT140* mutations were recently described in Mainzer-Saldino syndrome patients, and a subset of JATD patients with early end stage renal disease and frequent retinopathy.^{9 12} Besides *DYNC2H1* deficiency underlying JATD, 13 mutations have also been reported in patients with two of the severe short-rib polydactyly subtypes, Majewski syndrome (SRPS type II; MIM 263520)^{24 25} and Verma-Neumoff syndrome (SRPS type III; MIM 263510).^{13 26} One SRPS type II family carrying double heterozygous pathogenic mutations in both *NEK1* and *DYNC2H1* was also suggestive of possible digenic inheritance.^{24 25} *NEK1* dysfunction affects ciliogenesis and since the protein was localised to the basal body and within the cilium, a role in IFT was suggested.^{24 25}

The *DYNC2H1* protein, initially identified in sea urchin embryos,²⁷ is the central ATPase subunit of IFT dynein-2 complex, the principle minus-end directed microtubule motor that drives retrograde transport of the IFT-A particle to regulate tip-to-base transport.^{15 28 29} *DYNC2H1* has a typical dynein heavy chain organisation (figure 1) similar to other heavy chain dyneins underlying primary ciliary dyskinesia and other developmental disorders.^{34–39} *DYNC2H1* knockdown in *Caenorhabditis elegans* and mice results in short cilia with bulged tips,^{40 41} and Hedgehog signalling, an important signalling pathway that regulates bone development, is disrupted in *Dync2h1*-deficient mice as a result of defective retrograde IFT.^{41 42} The IFT dynein-2 protein complex is not yet fully defined^{28 43} but besides homodimers of *DYNC2H1* heavy chains,^{29 40 44} it likely contains the light intermediate chain *DYNC2LI1*^{45–48} and intermediate chain *DYNC2I1*.⁴⁹ Dynein light chains *DYNLL1/LC8*⁵⁰ and *DYNLT1/TCTEX1*^{43 51} have also been associated with the IFT dynein-2 complex.

Several factors have historically impeded genetic diagnosis in SRPS such as JATD, including extensive underlying genetic heterogeneity, small family sizes due to perinatal lethality and recently the large size of the *DYNC2H1* gene (90 exons) which make diagnostic analysis by Sanger sequencing expensive. Next generation sequencing (NGS) approaches of exome sequencing and targeted ciliome resequencing have more recently started to impact this field.^{8 9 12} Here, we investigated the contribution of *DYNC2H1* to JATD by mutational analysis in 57 families (71 affected patients) from two centres at UCL-ICH London and Radboud University Nijmegen Medical Centre, using a combination of single nucleotide polymorphism (SNP)-based homozygosity mapping, exome NGS and Sanger sequencing. We report a total of 34 mutations affecting 19/57 (33%) of families, and only two of these mutations have previously been associated with JATD. We show that *DYNC2H1* is a major cause of JATD, particularly affecting North Europeans, causing a predominantly thoracic phenotype. We also show that imaging of IFT in patient-derived cells potentially provides a useful diagnostic tool. The study confirms the potential of high throughput NGS to effectively identify the molecular basis of rare genetically heterogeneous diseases such as JATD, and to provide important new genotype–phenotype data that were previously very difficult to obtain.

METHODS

Patients

Inclusion criteria for the study were clinical and radiological signs of JATD (short ribs/ narrow thorax, small ilia with

acetabular spurs, short long bones and brachydactyly), and additional features such as renal disease, liver disease, retinopathy and polydactyly if present. The UCL samples had also all been excluded for *IFT80* mutations. A total of 71 JATD patient samples (61 UCL, 7 Nijmegen) fulfilling these criteria were processed by exome sequencing, and three Nijmegen samples were screened for *DYNC2H1* mutations by Sanger sequencing. All blood and skin biopsy samples were obtained with informed consent according to the approved guidelines of the local ethics committees and review boards.

SNP array and CNV analysis

Genotyping of 262 000 SNPs was performed using 250 K NspI Gene Chip Arrays (Affymetrix) according to the manufacturer's instructions, with genotypes extracted using Genotyping Console software (Affymetrix). PLINK⁵² was used homozygosity mapping and Copy Number Analyzer from Affymetrix GeneChip (CNAG) V2 software⁵³ for copy number variation (CNV) detection. All 'UCL' prefix London samples were analysed for CNVs using the *ExomeDepth* Program.⁵⁴

Whole exome sequencing

The exomes of patients JATD-1 and -2 were targeted with the Agilent SureSelect kit (Agilent V.1, 38 Mb) and sequenced on a quarter of a SOLiD four sequencing slide. Reads (50 bp fragments) were aligned to the Hg18 reference genome using Bioscope V.1.3, after which variants were called by the diBayes programme. Sample JATD-3 was targeted with the SureSelect kit (Agilent V.2, 50 Mb) and sequenced on a Life Technologies 5500XL instrument. Reads (50 bp fragments) were aligned to Hg19 reference genome, followed by variant calling using Lifescope V.2.1 software. London samples (prefixed 'UCL' in table 1) were either processed as part of the UK10K project for exome sequencing as previously described using the Agilent V.2 50 Mb All Exon kit⁵⁶ or using the Nimblegen V.3 kit (Axeq Technologies). Variants from all samples were annotated and prioritised to identify pathogenic mutations as previously described for Nijmegen samples^{8 22} and London samples.⁵⁶ Inclusion criteria for variants consisted of being covered by at least 10 sequence reads wherein the variant must be present in at least 20% of the reads (variants detected in 20%–80% of the sequence reads were considered heterozygous). Variants annotated in dbSNP132, the 1000 Genomes project, the Seattle exome database (<http://www.evs.gs.washington.edu>) or in our inhouse databases with an allele frequency above 0.5% were removed. An autosomal recessive inheritance model was applied for gene identification, with known JATD and SRPS genes manually analysed using the Integrative Genomics Viewer (<http://www.broadinstitute.org/igv/>). Candidate pathogenic variants were validated and assessed for familial segregation by Sanger sequencing.

Sanger sequencing

All 90 *DYNC2H1* (NM_001080463.1) exons not covered by whole exome sequencing (WES) or where the 250K SNP array indicated *DYNC2H1* as a primary candidate disease gene were analysed by Sanger sequencing. *DYNC2H1* primer pairs used have previously been published.¹³ PCR products were purified, sequenced and analysed as previously described.^{56 57}

Immunofluorescent microscopy

Patient and control fibroblasts obtained from skin biopsies under signed informed consent were seeded on cover glasses and grown for 24 h in Dulbecco's Modified Eagle Medium (DMEM) with 20% fetal calf serum (FCS), then serum starved




Figure 1 Mutations causing Jeune asphyxiating thoracic dystrophy (JATD). (A) Linear structure of the 4314 residue human DYNC2H1 protein showing the location of the 34 mutations described in this study in black, below the protein. Brackets indicate synonymous change associated with a splice site mutation. All previously reported DYNC2H1 mutations are shown above the protein, associated with JATD¹³ (black), short-rib polydactyly syndrome (SRPS II)^{24, 25} (red) and SRPS III^{13, 26} (orange). Conserved protein domains were taken from the consensus CDS entry for NP_001073932.1. The DYNC2H1 protein domains contain the six AAA+ domains of the hexameric ring-like ATP-hydrolysing motor domain, AAA1-AAA6: AAA1 (amino acids 1651–1875), AAA2 (aa. 1938–2161), AAA3 (aa. 2251–2505), AAA4 (aa. 2617–2863), AAA5 (aa. 3244–3479) and AAA6 (aa. 3697–3912). In addition, other domain-associated structures allow DYNC2H1 to function as a motor: a thin microtubule binding stalk domain between AAA4 and AAA5 for attachment to microtubules (MT-binding stalk, aa. 2881–3227); an N-terminal tail (DHC_N1, aa. 234–676); and a linker domain (DHC_N2, aa. 1120–1520) thought to change position in different nucleotide states to create the powerstroke for motility along microtubules; plus a conserved C-terminal domain arranged on top of the ATPase ring (Dynein_heavy, aa. 3621–4311).^{30, 31} (B) The predicted human DYNC2H1 protein is shown modelled to the resolved crystal structure of the cytoplasmic dynein heavy chain of *Dictyostelium discoideum* (DYHC_DICDI; PDB 3VKH)³² using Swiss-Model.³³ Amino acid residues 1204–2969 could be modelled with confidence; AAA1, blue; AAA2, lime green; AAA3, red; AAA4, dark grey. The chain B of 3VKH used for the modelling is highlighted in light grey. (C) The location of the DYNC2H1 missense mutations that map to the regions of the protein that were possible to model by homology are shown in black. (D) The p.R2481Q substitution missense mutation could create a new hydrogen bond between Q2481 and the conserved tyrosine (TYR) at position Y2477.

in DMEM with 0.2% FCS for 48 h. Cells were stained with antibodies against IFT88 (rabbit polyclonal, 1:100, kindly provided by G Pazour and rabbit polyclonal 1:200, 13967-1-AP from Proteintech), IFT57 (rabbit polyclonal, 1:250, kindly provided by G Pazour), acetylated α -tubulin (mouse monoclonal, 1:1000, T6793 from Sigma Aldrich) and RPGRIP1L (guinea pig polyclonal; SNC040, 1:500) as previously described.⁵⁷ Secondary antibodies used were Goat-anti-Mouse Alexa fluor 405, Goat-anti-Guinea pig 568 (both from Invitrogen, 1:500) and Goat-anti-Rabbit Alexa fluor 488 (Molecular Probes, 1:500). After staining, coverslips were mounted with a drop of Vectashield (Vector Laboratories) and imaged on a Zeiss Axio Imager Z1 fluorescence microscope (Zeiss) with ApoTome

attachment. Images were processed using AxioVision (Zeiss), Adobe Photoshop CS4 and Adobe Illustrator CS4 (Adobe Systems). A minimum of 100 cells per sample was assessed for cilia length and localisation of IFT proteins.

Web resources

- ▶ Online Mendelian Inheritance in Man (OMIM) (<http://www.ncbi.nlm.nih.gov/Omim>)
- ▶ University of California, Santa Cruz (UCSC) Genome Browser (<http://www.genome.ucsc.edu>)
- ▶ The Consensus CDS (CCDS) project (<http://www.ncbi.nlm.nih.gov/projects/CCDS/>)
- ▶ PLINK (<http://pngu.mgh.harvard.edu/~purcell/plink/>)

Table 1 Clinical information for *DYNC2H1* JATD patients

Family	Patient	Origin	Sex	Age range of patient	Related parents	Hands	Feet	Rib cage	Limbs	Short stature/height percentile	Skeleton anomaly	Liver, kidney, eye features	Remarks
JATD-1 (Case 4*)	II-2	Dutch	M	20s	No	No polydactyly, metacarpals and phalanges radiologically normal	No polydactyly	Narrow, short, broad ribs, thorax; surgically corrected	Mild shortening radius/ulna in infancy	P50	Trident appearance of acetabular margins; handlebar clavicles	Thoracic scoliosis (convex to right); no renal or retinal involvement	Chest pain during and after exercise and stress; hypovascular pancreas lesion
JATD-2 (Case 5*)	II-1	Dutch	M	20s	No	Short distal carpals and distal phalanges in infancy; brachydactyly	No polydactyly,	Narrow, short, horizontal ribs	Short limbs in infancy	P25–50	Short iliac bones with spur-like protrusions; handlebar clavicles	Thoracolumbal scoliosis (convex to left); no renal or retinal involvement	Syndactyly of digits 2 and 3 (both feet); hallux valgus (right), short breath during sport
JATD-3 (Case 6, 7*)	II-4	Dutch	M	Late teens	Yes	Possible brachydactyly (not pronounced); no polydactyly	No polydactyly	Small, bell-shaped thorax with short, broad ribs and short sternum	Shortened limbs in infancy	At the age of 12 years height below the third centile	Abnormal pelvic configuration with acetabular spiky protrusions; elevated clavicles	No renal or retinal abnormalities	Respiratory distress after birth, which improved after hours
	II-5	Dutch	M	Died 2nd month (respiratory insufficiency)		No polydactyly	No polydactyly	Narrow thorax, short ribs	Short limbs	NA	Trident appearance of acetabular margins; elevated clavicles	Signs of mild retinitis pigmentosa, bile duct proliferation and portal tract fibrosis, renal mesangial glomerular sclerosis	Severe respiratory distress at birth; lung hypoplasia with interstitial fibrosis; cardiac septum defect; cerebral ventriculomegaly
JATD-4 UCL47	UCL47.1	Dutch	F	30s	No	Brachydactyly; no polydactyly	Brachydactyly; no polydactyly	Narrow	Mild shortening	P50–75	Acetabular spurs, small ilia	Mildly disturbed liver enzymes; normal vision, normal renal ultrasound	
JATD-5 UCL61	UCL61.1	Dutch	M	Fetus	No	No polydactyly	No polydactyly	Extremely narrow	Short arms and short bowed femur	NA (fetus)	Acetabular spurs	Large kidneys on ultrasound in utero	
JATD-6	II-1	Dutch	M	Under 10	No	No polydactyly	No polydactyly	Narrow	Mild shortening	P10–25. (height 109 cm at 5 years 6 months)	Small ilea with acetabular spurs; brachydactyly, mild rhizomelic shortening (neonatally)	No renal or retinal involvement	Hernia inguinalis; exorotation of legs; chest and leg pain induced by exercise
JATD-7 UCL19	UCL19.1	Belgian	NA	Fetus	No	No polydactyly. Short and broad hands, short fingers; fixed extension of the first interphalangeal joints	No polydactyly	Very narrow, tubular	Short long bones with irregular metaphysis and bony spikes at the ends	NA	Normal vertebrae. Short ilia with typical medial bony projection		Perimembranous VSD
JATD-8 UCL63	UCL63.1	German	F	Under 10	No	No polydactyly	No polydactyly	Narrow thorax, short horizontal ribs	Very mild shortening	P50–75	Small ilia, acetabular spurs	No renal disease, liver disease or retinopathy	

Continued

Table 1 Continued

Family	Patient	Origin	Sex	Age range of patient	Related parents	Hands	Feet	Rib cage	Limbs	Short stature/ height percentile	Skeleton anomaly	Liver, kidney, eye features	Remarks
JATD-9	II-1	Polish	F	Under 5	Yes	No polydactyly, mildly rhizomelic shortening of upper limbs and large hands	No polydactyly	Very narrow, pectus carinatus		P90	Anterior of ribs ossified with wide rounded margins, phalanges have cone-shaped epiphysis, short shafts of phalanges and metacarpal bones. ~2 years advanced bone age	Normal abdominal ultrasound, no signs of retinal disease	Mild respiratory problems after birth high forehead, widely spaced teeth
JATD-10 UCL15	UCL15.1 UCL15.2 UCL15.3	UK Ashkenasi	NA NA NA	Fetus Fetus Fetus	No	No polydactyly	No polydactyly	Narrow	Short femur	NA (fetus) NA (fetus) NA (fetus)	Small ilia, typical acetabular spurs		
JATD-11 UCL90	UCL90.1	UK	F	Under 5	No	No polydactyly	No polydactyly	Narrow, asymmetric shape	Mildly shortened upper and lower extremities in early childhood	Slightly short stature	Pelvis radiologically compatible with JATD	No retinal, renal or liver disease	Delayed motor milestones (walking with 2.5 years of age), valgus deformity of the feet
JATD-12 UCL48	UCL48.1 UCL48.2 UCL48.3	UK	F M F	Died as neonate Fetus Fetus	No	No polydactyly	No polydactyly	Narrow, severe shortening of ribs with bulbous anterior ends	Mild shortening long bones, slight bowing of femurs. Mildly shortened tubular bones of hands	Limbs <5th centile at 20/40, chest size queried NA (fetus) NA (fetus)	Horizontal acetabular roof with medial and lateral spurs, narrow sciatic notches and short iliac wings—trident pelvis	Long superiorly placed clavicles. No renal, retinal or liver disease	Severe respiratory distress at birth, died within hours of birth
JATD-13 UCL39	UCL39.1	Caucasian USA	M	Under 10 (loss of follow-up)	Yes	NA	NA	Narrow		NA (not documented)	NA	NA	
JATD-14 UCL80	UCL80.1 UCL80.2	Turkish	M F	Died in 1st year (respiratory failure) Died at 1.5 years (pneumonia)	Yes	No polydactyly, cone-shaped epiphyses No polydactyly	No polydactyly No polydactyly	Severely narrowed Mild narrowing	Short long bones Short long bones	<P3 in infancy <P3 in infancy	Trident acetabulum, acetabular spurs, small ilia	Severe respiratory distress Frequent chest infections; no renal or retinal involvement	Albinism
JATD-15 UCL58	UCL58.1	Turkish	M	Died at 1.5 years (respiratory failure)	Yes	No polydactyly	No polydactyly	Tubular bell-shaped thorax	Mildly shortened extremities	P3 at 1.5 years	Dysplastic acetabulum	Normal kidney function (unilateral renal pelvic ectasia seems unrelated to JATD), no liver disease, no retinopathy	Valgus deformity of the feet, mild frontal bossing, left sided testis hydrocele, patent ductus arteriosus
JATD-16 UCL81	UCL81.1	Turkish	M	Mid-teens	Yes	Unilateral postaxial polydactyly	No polydactyly	Narrow	Mild shortening	P97 at 9 years	Trident acetabulum, acetabular spurs; handlebar clavicles	Elevated liver enzymes since age 7 years; no renal or retinal involvement	Unilateral atresia of external ear meatus and ear anomaly

Continued

Table 1 Continued

Family	Patient	Origin	Sex	Age range of patient	Related parents	Hands	Feet	Rib cage	Limbs	Short stature/ height percentile	Skeleton anomaly	Liver, kidney, eye features	Remarks
JATD-17 UCL95	UCL95.1	Turkish	F	Under 5	No	No polydactyly	No polydactyly	Narrow	Short limbs in early childhood	P3–10 at 3 years	Pelvis and thorax radiologically compatible with JATD	Normal renal function and ultrasound, no retinitis pigmentosa, normal liver function	Short neck, elevated clavicular
	UCL95.2		M	Died at first day of life (respiratory failure)				Narrow	Short limbs	NA		No signs of renal, retinal or liver disease	
	UCL95.3		F	Fetus				Short ribs	Short extremities	NA		NA	
JATD-18 UCL62	UCL62.1	Turkish–Kurdish	M	Under 5	No	No polydactyly	No polydactyly	Severely narrow			Pelvis and thorax radiologically compatible with JATD	No renal or retinal disease	Oesophageal atresia
	UCL62.2			Under 5		No polydactyly, broad hands, short fingers	No polydactyly	Milder narrowing	Broad hands and toes, slightly short fingers	NA			
JATD-19 UCL109	UCL109.1	UK Yemen–Somali	M	Under 5	No	No polydactyly	No polydactyly	Severely narrowed		Height NA, not obviously below average	Pelvis and thorax radiologically compatible with JATD	No renal or retinal involvement	Severe respiratory distress, tracheostoma, currently on home ventilation at night
	UCL109.2		M	Under 5				Narrow				No renal or retinal involvement	Very mild respiratory symptoms

*Patient previously described.⁵⁵ Ages approximated to protect patient privacy. Clinical details relate to information taken at ascertainment or at most recent review, indicated in 'age range' column. Retinal disease was excluded in most patients with fundoscopy.

JATD, Jeune asphyxiating thoracic dystrophy; IFTB, intraflagellar transport complex B; NA, not available; UCL, University College London; VSD, ventricular septum defect.

- ▶ Copy Number Analyzer for Affymetrix GeneChip (<http://www.genome.umin.jp/>)
- ▶ GraphPad, Quick Calcs (<http://www.graphpad.com/quickcalcs/chisquared2.cfm>)
- ▶ Polyphen2 (<http://genetics.bwh.harvard.edu/pph2/>)
- ▶ Mutationtaster (<http://www.mutationtaster.org/>)
- ▶ Sorting intolerant from tolerant (SIFT) (<http://sift.jcvi.org/>)
- ▶ Genomic evolutionary rate profiling (GERP) (<http://mendel.stanford.edu/SidowLab/downloads/gerp>)
- ▶ PhyloP (<http://genome.ucsc.edu>)
- ▶ Alamut (<http://www.interactive-biosoftware.com/software/alamut/features>)

RESULTS

DYNC2H1 mutations are a major genetic cause of JATD

In total, we detected causative (biallelic) *DYNC2H1* mutations in 29/71 patients (41%) from 19/57 families (33%) with JATD. The patient's clinical information is provided in table 1, and the detected mutations are summarised in table 2. We validated all *DYNC2H1* variants identified by exome sequencing with Sanger sequencing, and tested whether the variants segregated with disease in all families. In all cases the segregation pattern was consistent with a recessive inheritance pattern (see online supplementary figure S1), and none of the mutations were identified in 500 inhouse control exomes with an allele frequency >0.005. Although the majority of these families were solved directly through exome sequencing, *DYNC2H1* was initially not targeted in the Agilent V.1 (38 Mb) exome kit. Still, sufficient coverage was generated for 30% of the *DYNC2H1* exons due to the capture by enrichment probes targeting homologous regions (ie, coverage was generated for regions that were not contained in the exome design). Somewhat surprisingly, this resulted in the detection of a heterozygous p.D3015G variant (table 2) in JATD-1 and -2, through capturing the correct regions despite their not being targeted. This mutation was validated by Sanger sequencing using a locus specific and relatively long (450 bp) PCR amplicon.

With the improved Agilent V.2 50 Mb kits, the entire *DYNC2H1* gene was targeted, and this significantly improved coverage to approximately 90% of all coding exons, using a 'calling-on-target' strategy. A comparison of coverage across the *DYNC2H1* gene for the different exome sequencing kits used for screening is shown in online supplementary figure S2. In parallel, targeted Sanger sequencing of the initially non-covered *DYNC2H1* exons was performed, which revealed mutations previously missed by WES in patients JATD-1, -2 and -10 (table 2). These data show that WES, despite its revolutionary improvements for gene sequencing, also poses challenges for mutation identification in research and DNA diagnostic settings.

All Nijmegen samples were analysed using SNP microarray analysis prior to exome sequencing and this had excluded larger CNVs in all patients apart from one deletion of exons 81–83 identified in patient JATD-6, who additionally carried two heterozygous missense changes identified by Sanger sequencing. In comparison with Sanger sequencing, NGS data also offers the opportunity to identify CNVs; London exomes underwent CNV analysis using ExomeDepth⁵⁴ and we identified a large heterozygous deletion encompassing the last three exons of *DYNC2H1* exons in patient JATD-7, in addition to a missense mutation detected by conventional WES analysis (see online supplementary figures S2 and S3, table 2). Finally, we also identified mutations in the consanguineous family JATD-9 through SNP array-based homozygosity mapping followed by targeted Sanger sequencing.

Mutations causing nonsense, frameshift and essential splice site changes were judged to be disease causing, and the identified variants were also assessed for their pathogenic potential using five different bioinformatics tools (see online supplementary table S1). These incorporate evolutionary conservation of residues to gauge their functional importance; corresponding multispecies alignment of all variants is shown in online supplementary figure S4. While most mutations are clearly predicted to impair protein function by most of the tools used, three missense alleles gave more equivocal results: p.R2481Q, p.M2227V and p.M1379V. p.R2481Q is rather poorly predicted for pathogenicity; however, there is high evolutionary conservation at this residue (see online supplementary figure S4) and it is carried in JATD-3 in combination with a nonsense change. The effect of p.R2481Q was modelled onto the predicted *DYNC2H1* protein, showing that substitution of a glutamate at this residue potentially significantly affects the tertiary structure, leading to a new hydrogen bond between Q2481 and the conserved tyrosine at position Y2477 (figure 1C). p.M2227V in JATD-17 was found as a homozygous change and p.M1379V in JATD-11 as a heterozygous change. Protein modelling of these substitutions on the tertiary model of *DYNC2H1* did this not reveal any suggested mechanism for their pathogenic effect (data not shown). Both are predicted as benign by Polyphen-2 but as deleterious by SIFT and predicted to create new splice donor sites by Mutation Taster; moreover, the second allele in JATD-17 is a nonsense allele (p.L4177Ffs*29) and in JATD-11 is in an early and essential splice site predicting abolishment of the exon 1 splice donor.

The heterozygous p.P2797_L2799del in JATD-15 creates an inframe loss of three amino acids which cannot be scored by the software, but these residues proline-alanine-leucine (PAL) are highly conserved and thus their loss is likely to be functionally important (see online supplementary figure S4). Finally, variants in JATD-16 (c.7437+3A>G) and JATD-18 (c.2346–5T>G) are the only splice site mutations not affecting a 100% conserved splice site nucleotides. However, both still affect a highly conserved splice site nucleotide, are predicted by Mutation Taster to cause splice defects, and also have significant GERP, SIFT and PhyloP conservation scores; moreover, the second variant in both cases is strongly predicted to be pathogenic. Patient material was not available from either family, preventing an assessment of the relevance of these variations at the RNA level.

DYNC2H1 mutational spectrum in JATD

The *DYNC2H1* mutation distribution is summarised in table 2 and figure 1. A total of 34 likely pathogenic *DYNC2H1* variants were identified as likely to be causal in 29 patients from 19 families. These comprised six splice site mutations and seven nonsense/deletion/frameshift 'null' mutations that were never seen in combination together, in addition to 21 missense changes (figure 1A). Overall, 30/34 mutations were private, while three have been previously reported: p.D3015G and p.I1240T each in one JATD patient¹³ and p.R330C in an SRPS II patient.²⁴ The p.D3015G mutation seems to occur only in North European patients so far, and could represent a founder allele in this population. p.Glu436*, not previously reported, was present in two unrelated Dutch families JATD-1 and -4.

Biallelic mutations were identified in 16/19 families, but more than two were identified in JATD-5, -6 and -17. The JATD-5 allele p.L1228I is a polymorphism not annotated as pathogenic (*rs189806840*), and therefore is the most likely to be excluded as a disease cause. JATD-6 carried the common mutation p.D3015G, and a large deletion p.G3891_Q4020; the third variant is a heterozygous missense change p.R3813C. Together with a well-

Table 2 Identified *DYNC2H1* mutations

Family	Nucleotide change	Mutation	Var	Location	ID method	Remarks	Functional validation
JATD-1	c. 90443A>G	p.D3015G	Het	Exon 57	WES (Agilent 38 Mb)	rs137853027†	~50% of cilia have bulged tips filled with IFT-B proteins, normal cilia length. rs137853027: minor allele frequency (EVS) 3 in 11957 alleles (0.00026 or 0.026%)
	c. 1306G>T	p.E436*	Het	Exon 9	SS		
JATD-2	c.9044A>G	p.D3015G	Het	Exon 57	WES (Agilent 38 Mb)	rs137853027†	~50% of cilia have bulged tips filled with IFT-B proteins, normal cilia length. rs137853027: Minor allele frequency (EVS) 3 in 11957 alleles (0.00026 or 0.026%)
	c.3459-1G>A	Exon 24 splice acceptor	Het	Intron 23	SS		
JATD-3	c.9817C>T	p.E3273*	Het	Exon 62	WES (Agilent 50 Mb)		~ 15% of cilia have bulged tips filled with IFTB proteins, normal cilia length
	c.7442G>A	p.R2481Q	Het	Exon 46			
JATD-4	c.1306G>T	p.E436*	Het	Exon 9	WES (Agilent 50 Mb)		
	c.8457A>G	p.I2819M	Het	Exon 53			
JATD-5	c.3682C>A	p.L1228I	Het	Exon 25	WES (Nimblegen V.3)	rs189806840 (dbSNP)	rs137853027: Minor allele frequency (EVS) 16 in 11820 alleles (0.00135 or 0.135%)
	c.7663G>A	p.V2555M	Het	Exon 47			
	c.7718A>G	p.Y2573C	Het	Exon 48			
JATD-6	14kb deletion (g.103191405-103204921)	p.G3891_Q4020del	Het	Del exons 81–83	SNP microarray CNV analysis and SS	rs137853027†	rs137853027: minor allele frequency (EVS) 3 in 11957 alleles (0.00026 or 0.026%)
	c.9044A>G	p.D3015G	Het	Exon 57	SS		
	c.11437C>T	p.R3813C	Het	Exon 79	SS		
JATD-7	c.10163C>T	p.P3388L	Het	Exon 67	WES (Agilent 50 Mb)	Exome CNV analysis	
	c.12480_13556del (g.103325916-103350592)	p.N4160_Q4314del	Het	Del exons 87–90			
JATD-8	c.3719T>C	p.I1240T	Het	Exon 25	WES (Agilent 50 Mb)	rs137853028†	rs137853028: not seen in EVS
	c.12716T>G	p.L4239R	Het	Exon 89			
JATD-9	c. 11560T>G	p.W3854G	Hom	Exon 80	HZ mapping (250 K) then SS		
JATD-10	c.6910G>A	p.A2304T	Het	Exon 43	SS	3 affected sibs	
	c.8389_8397delCCAGCTTTG	p.P2797_L2799del	Het	Exon 52	WES (Agilent 50 Mb)		
JATD-11	c.195G>T	p.T65T	Het	Exon 1 splice donor	WES (Agilent 50 Mb)		
	c.4135A>G	p.M1379V	Het	Exon 27			
JATD-12	c.312_313delTA	p.P104PfsX*2	Het	Exon 2	WES (Agilent 50 Mb)	3 affected sibs	
	c.5972T>A	p.M1991K	Het	Exon 38			
JATD-13	c.4325G>A	p.G1442D	Het	Exon 28	WES (Agilent 50 Mb)		
	c.1953G>A	p.K651K	Het	Exon 13 splice donor			
JATD-14	c.988C>T	p.R330C	Hom	Exon 6	WES (Agilent 50 Mb)	2 affected sibs	
JATD-15	c. 7594C>T	p.R2532W	Hom	Exon 47	WES (Agilent 50 Mb)		
JATD-16	c.7437+3A>G	Exon 45 splice donor	Het	Intron 45	WES (Agilent 50 MB)		Normal cilia length
	c.7539A>T	p.G2513G	Het	Exon 46 splice donor			
JATD-17	c.6679A>G	p.M2227V	Hom	Exon 42	WES (Agilent 50 Mb)		
	c.12538delC	p.L4177Ffs*29	Het	Exon 87			
JATD-18	c.2346-5T>G	Exon 17 splice acceptor	Het	Intron 16	WES (Agilent 50 Mb)	2 affected sibs	
	c.7085A>G	p.N2362S	Het	Exon 43			
JATD-19	c.7919T>C	p.I2640T	Het	Exon 49	WES (Agilent 50 Mb)	2 affected sibs	
	c.2612T>C	p.L871P	Het	Exon 18			

†Annotated as pathogenic in dbSNP due to previous publication.¹³ EVS, NHLBI Exome Variant Server (<http://evs.gs.washington.edu/EVS/>). Functional validation refers to analysis in ciliated patient-derived fibroblasts. Nucleotides numbered according to Ensembl transcript *DYNC2H1-005 ENST00000398093*.

WES, whole exome sequencing with Agilent 38 or 50 Mb kit or Nimblegen V.3 kit; SS, Sanger sequencing; HZ mapping, SNP array-based homozygosity mapping. CNV, copy number variation; IFT, intraflagellar transport; JATD, Jeune asphyxiating thoracic dystrophy; SNP, single nucleotide polymorphism.

*Indicates a stop codon insertion.

supported heterozygous frameshift mutation p.L4177Ffs*29, JATD-17.1 carries a homozygous missense p. M2227V.

The 21 missense mutations were distributed along the length of DYNC2H1 (figure 1A); however, some clustering was evident since the majority (16/21) were localised to defined functional heavy chain protein domains, mainly the AAA+ motor domain, rather than to protein areas in between defined domains (figure 1A). This clustering focused around the AAA3 and AAA4 domains which contained 8/21 missense changes (38%), with fewer in AAA2, AAA5 and AAA6, and none present in AAA1. Fisher's exact test was used to evaluate the missense mutation distribution, comparing windows of 100 subsequent amino acids along the DYNC2H1 protein. This revealed a statistically significant enrichment ($p < 0.01$) of mutations between the AAA3 and AAA4 domains (see online supplementary figure S5), although after correcting for multiple hypothesis testing using False Discovery Rate this enrichment is no longer statistically significant (see online supplementary figure S5). We compared the DYNC2H1 mutation distribution with that of DNAH5 which is mutated in a different ciliopathy, primary ciliary dyskinesia, where mutations are considered to be highly deleterious in their effect leading to complete loss of the DNAH5 protein.^{35 58–60} The distribution of DNAH5 missense mutations mirrored that of DYNC2H1 since they also clustered to the functional domains of DNAH5 ($p < 0.01$), and similarly this significance was lost after False Discovery Rate multiple hypothesis testing correction (see online supplementary figure S5).

The total number of DYNC2H1 missense mutations analysed are too small to make robust conclusions; however, this trend in the findings warrants further investigations to shed new light on the functional role of DYNC2H1 in JATD. Figure 1C illustrates this tendency of DYNC2H1 missense mutations to localise within the known functional domains in a 3D model of the protein, including the AAA domains. It was possible to determine the location of 14 of the missense changes within the tertiary structure of the protein (figure 1C) by homology modelling to the most advanced crystal structure of the protein, which has been determined in *Dictyostelium discoideum* (figure 1B).³²

Variable thoracic phenotype severity in JATD patients with DYNC2H1 mutations

DYNC2H1 mutations in our genetically defined JATD cohort primarily result in defects of the skeleton. The clinical course was dominated by abnormal bone development (figure 2A–E), universally affecting the thorax cage due to a reduced rib length. Typical handlebar clavicles were observed (see online supplementary figure S6). The scoliosis evident in JATD-1 and -2 could be part of the primary skeletal phenotype; this should thus be regularly monitored (figure 2J). Several patients have brachydactyly with cone-shaped epiphyses but this was not universal; for example, brachydactyly and cone-shaped epiphyses were absent in JATD-1 and -16 (see online supplementary figure S6). Since cone-shaped epiphyses tend to only be visible after the first year of life, the age at observation becomes a factor when estimating their incidence; both JATD-1 and -16 did not have hand x-rays as adults, so we cannot exclude their later development. Bilateral polydactyly was not observed (JATD-16 had unilateral postaxial polydactyly). Although short stature with variable shortening of the limbs accompanied by some bowing was frequently found in early childhood, in adolescence and adulthood average height was reached in most cases. Most patients had pelvic abnormalities with small ilia and typical acetabular spurs. Strikingly, we observed a high variability in rib shortening ranging from a slightly narrowed chest through to severe narrowing leading to death in infancy, with a consequently

variable degree of respiratory problems (figure 2F–I and table 1). These differences were observed between patients with different DYNC2H1 mutations, and also between siblings with identical DYNC2H1 genotypes, for example, in JATD-3, -18, -19 and JATD-14 (Table 1, figure 2H,I). Some cases showed an improvement of the disproportionate thorax with age (figure 2M–Q and online supplementary figure S6).

Low incidence of renal or retinal disease in JATD patients with DYNC2H1 mutations

Although there are several older patients (young adults or adolescents) in our cohort, we identified renal and/or retinal abnormalities in only two affected individuals from families JATD-3 and -5. These were both generally more severe cases in whom these features were detected at a very young age, in the second month of life (JATD-3) and *in utero* (JATD-5). The finding that neither kidney disease nor retinopathy occur frequently in JATD patients with DYNC2H1 mutations in our cohort seems to contrast with clinical findings in JATD patients carrying mutations in IFT140, where a high frequency of kidney disease and retinopathy has been found.^{9 12} However, as some of our DYNC2H1 patients represent terminated fetuses and not all patients have reached adulthood, we cannot exclude the possibility that additional symptoms may develop in the future. Mild liver disease was diagnosed in JATD-5 and -16, and bile duct proliferation and portal tract fibrosis in JATD-3 (table 2). This overall lack of significant renal, hepatic and pancreatic involvement is consistent with previously reported JATD DYNC2H1 cases.¹³ There were other features in the cohort but these have not been associated with JATD and are most likely unrelated, including cardiac septum defects, oesophageal atresia, albinism, unilateral ear malformation, bilateral toe syndactyly, patent ductus arteriosus and testicular hydrocele (figure 2K,L).

IFT defects in ciliated fibroblasts from patients with DYNC2H1 mutations

Accumulations of anterograde transport proteins in ciliary tips are typical cellular defects observed when retrograde IFT transport is disrupted. We previously showed accumulations of the IFT-B proteins IFT57 and IFT88 in fibroblasts derived from patients with skeletal ciliopathies due to mutations in IFT43, WDR35/IFT121 and WDR19/IFT144 that are all part of the IFT-A protein complex.^{8 21 22} We also found this cellular phenotype in three of the JATD patients with defined DYNC2H1 mutations in this study, consistent with a disruption to IFT-A retrograde transport due to DYNC2H1 deficiency. However, we saw different severity across samples. Whereas accumulations of IFT-B proteins IFT57 and IFT88 occurred in 50%–60% of fibroblasts derived from patients JATD-1 and -2, only 15% of cells were affected in JATD-3 (figure 3A–D, online supplementary figures S7 and S8). There was no major effect on ciliary length compared with controls (patients JATD-1, -2, -3 and -16, data not shown).

DISCUSSION

To our knowledge, this is the largest WES-related study performed in JATD so far, comprising 71 patients from 57 families. Our data indicate that DYNC2H1 is the most frequent overall cause of JATD, accounting for 33% of the families screened in this study. The high mutation frequency in JATD may be influenced by the size of the DYNC2H1 protein and its central role in ciliary IFT. Since none of the DYNC2H1 patients have many extra-skeletal findings, the frequency could also reflect a higher survival rate of DYNC2H1 patients compared with those carrying mutations in other JATD-related genes.




Figure 2 Clinical features of *DYNC2H1* patients. (A–E) Hallmarks of Jeune asphyxiating thoracic dystrophy (JATD): (A, JATD-5; B, JATD-16) Small thorax due to short ribs; (A, JATD-5, B, JATD-16, C, JATD-5, D, JATD-14) Small ilia with acetabular spurs; (C, JATD-5, D, JATD-14) Shortening of femurs, accompanied by bowing in (D, JATD-14); (E) 3D reconstruction of CT images of patient JATD-4. (F–I) Severity of the rib shortening varies between different patients from different families carrying *DYNC2H1* mutations as well as between affected siblings: while patient JATD-5 presents with extremely shortened ribs (F), patient JATD-18 (UCL62.2) is only mildly affected (G). (H, I) Patient JATD-14 (H, UCL80.1) is markedly more severely affected than his sister JATD-14 (I, UCL80.2). (J–L) Additional features: (J) scoliosis in JATD-2, (K) syndactyly in JATD-2, (L) ear malformation in JATD-16. (M–Q) Thoracic narrowing becomes less pronounced with increasing patient age. (M) Shows patient JATD-16 at under 5 years; the same patient is shown a few years later in (N) at under 10 years. (O) Patient JATD-3 in his 20s, (P) patient JATD-2 in his late teens, (Q) patient JATD-1 in his mid-20s these cases have less pronounced thoracic phenotypes compared to birth or infancy, as described in the text. Note also that shortening of the upper limbs seems less severe when JATD patients reach adolescence.

We identified 34 *DYNC2H1* mutations, 30 of which were novel, and found these to occur more frequently in JATD patients of Caucasian and Turkish origin than in patients of African and Asian ethnic background. While *DYNC2H1* mutations account for 54% of the Caucasian cases we screened, and 38% of screened Turkish cases, we only detected one case of biallelic *DYNC2H1* mutations in other ethnicities (15 cases screened, representing <10% of total cases, data not shown). This might partly be due to European founder effects, at least for p.D3015G, which we found in three Dutch families and which was previously reported in a French family,¹³ and perhaps also for two other mutations, that is, p.I1240T, which was detected in German and French families that are described in this study and previously,¹³ and p.E436*, which we identified in two Dutch families here. One other mutation was also found repetitively, p.R330C, albeit in families of different geographical origin: a Turkish JATD family in this study and previously in a SRPS type II patient of Haiti origin.²⁴

Considering only the *DYNC2H1* missense mutations, which can indicate important functional clues about disease causing mechanisms, the majority that we and others have described tend to localise to the known, conserved functional domains of *DYNC2H1*. This is similar to the mutation distribution determined in *DNAH5*, the heavy chain dynein gene mutated in patients with primary ciliary dyskinesia, adding support to the evidence for the *DYNC2H1* variants being causal JATD alleles. Remarkably, a large number of the *DYNC2H1* missense mutations localised to the region of the protein spanning AAA3-AAA4; furthermore, p.D3015G, the most common overall mutation is localised in close proximity within the microtubule-binding stalk region. In contrast, we did not identify any mutations in the AAA1 domain, which is the main ATP hydrolytic site of the *DYNC2H1* motor domain and the primary driver of HC dynein's microtubular movement.⁶¹ Although AAA3 and AAA4 are very important for ATP binding, their influence on ATP binding and microtubule sliding activities




Figure 3 Intraflagellar transport (IFT-B) accumulations in ciliary tips in Jeune asphyxiating thoracic dystrophy (JATD) patient fibroblasts. (A) In contrast to wild type fibroblasts (controls 1 and 2) in which IFT88 localises primarily to the ciliary base (and to a much lesser amount to the tip), IFT88 concentrates distally in cilia in fibroblasts derived from JATD-1, -2 and -3 family patients. Cells that were analysed in JATD-3 are derived from affected individual II-4 (Table 1). Per condition at least 100 cells stained for IFT88, acetylated- α tubulin (marker for the ciliary axoneme) and RPKGIP1L (marker for the ciliary base) as displayed in panel C were independently analysed by two blinded researchers. The control fibroblast lines were derived from individuals unrelated to our JATD patients. The graph shows that 64%, 59% and 14% of cells from patients from families 1, -2 and -3 demonstrate IFT88 concentrations in ciliary tips, whereas this effect is only observed in 3% and 2% of the cells from controls 1 and 2, respectively. (B) Another IFT-B complex partner IFT57 also accumulates in ciliary tips of JATD fibroblasts. While 53% and 50% of ciliated fibroblasts from JATD-1 and -2 patients demonstrate IFT57 accumulations in the ciliary tips, only 2% of the cells of the control display this cellular phenotype (also see panel D). Cells were analysed as per (A). (C) Compared with controls, IFT88 accumulates in distal ends of cilia in fibroblasts from JATD-1 and -2 patients. The images show a single cilium per patient or control in detail. Cells were stained with anti-IFT88 (green); antiacetylated α tubulin (marker for the ciliary axoneme, cyan); and anti-RPKGIP1L (marker for the ciliary base, red). Whole-field images displaying multiple cilia are available in online supplementary figure S7. (D) Like IFT88, IFT57 collects distally in cilia in fibroblasts from JATD-1 and -2 patients. Cells were stained with anti-IFT57 (green); antiacetylated α tubulin (purple); and anti-RPKGIP1L (red). Whole-field images displaying multiple cilia are available in online supplementary figure S8.

is less than AAA1, and they probably play a more regulatory role.^{31 61} This importance could explain why currently no AAA1 domain mutations were identified, as variants affecting AAA1 function may be embryonic lethal in effect. A number of missense variants also cluster in the N-terminal linker region DHC-N2, which is thought to be the motile element of the

dynein heavy chain, essential for its movement along the microtubules.^{62 63}

These data collectively suggest that JATD *DYNC2H1* missense mutations would alter protein function, but may be 'mild' or hypomorphic in their effect. In agreement, although seven putative 'null' nonsense, frameshift or deletion mutations were

identified, no patients carried these in biallelic form, and none were biallelic for any of the six splice site mutations either. This presumed lack of a completely abolished protein function in surviving patients has been previously reported for lethal ciliopathy disorders including JATD.^{7 11 12} Experimental data using knockout mouse models indeed suggest that JATD null alleles are incompatible with mammalian development beyond mid-gestation.^{42 64}

Using the IFT-B proteins IFT57 and IFT88 as markers in patient fibroblasts, we showed that retrograde IFT transport is disrupted as a result of loss of *DYNC2H1* function, since these anterograde transport proteins accumulate in the ciliary tips. However, this effect was variable between JATD patient samples, consistent with a previous report.⁸ Thus, in the diagnostic setting it is possible that immunofluorescence studies may be of help to narrow down which aspect of IFT is deficient before the molecular defect has been defined, and second, they could provide additional evidence that a candidate gene from exome sequencing is likely the disease causing gene. However, further studies are needed to evaluate the specificity of this test. Currently we can only speculate based on the known biological roles of these proteins that we would not also find an accumulation of IFT-B particles at ciliary tips in fibroblasts of patients with such defects. Furthermore, we have not performed any comparative immunofluorescence studies in fibroblasts derived from patients with mutations in genes encoding anterograde IFT-B proteins such as IFT80, or proteins not known to be directly involved in IFT such as *NEK1*, to determine any specific differences in their IFT protein accumulations.

No major differences were observed in cilia number and length in fibroblasts from JATD patients, while fibroblasts from more severely affected patients with SRPS type III were previously reported to be significantly shorter and displaying bulged ciliary tips matching with defective IFT.²⁶ Similar observations of short, bulged cilia and conclusions that this results from deficient retrograde IFT have been reported in *Dync2h1* knockout mice.⁴¹ The different findings in mice compared with the *DYNC2H1* patients reported here may reflect a difference between the mouse null allele and the putative hypomorphic alleles revealed in the JATD patients. In line with this is the finding that a hypomorphic *Ift80* genetrapped mouse which retains partial protein expression has also been found to form cilia of normal length.⁶⁴ The reasons for the shorter cilia observed in more severe SRPS cases caused by *DYNC2H1* mutations are a matter of speculation at this point, but could reflect a different mutation mechanism for specific DNA variants that are more deleterious to protein function, and/or may arise from an increased mutational load, that is, additional mutations in other ciliary genes influencing the phenotype in these patients.

A lack of extra-skeletal involvement was apparent for the 19 JATD families carrying *DYNC2H1* mutations, apart from a few cases with renal anomalies and/or mildly elevated liver enzymes, or features that have not previously been described to be associated with JATD. Most of these features such as digit 2/3 syndactyly or unilateral ear malformation are likely to be unrelated as they occur quite frequently in the normal population, and being 'minor birth defects' they might often not even be reported; indeed, the 2/3 syndactyly in family JATD-2 was present in family members unaffected by JATD. Conversely, it is difficult to reconcile how these features which include a rather high frequency of mild cardiac septal defects occur as unrelated features, since we have no explanation for their occurrence. The lack of extra-skeletal involvement is consistent with the 13 *DYNC2H1* patients previously reported, since renal, hepatic and

pancreatic abnormalities were seen in 5/13, but only cases with severe SRPS disease, none with JATD.^{13 24-26} We also found that patients can 'grow out' of their thoracic and short stature phenotype as they get older, and that very often death due to respiratory failure seems to be limited to the first year of life, which is consistent with previous reports.⁵⁵ JATD patients carrying *IFT80* mutations also seem to exhibit a primarily thoracic phenotype,¹⁰ but apart from this observation no major phenotype-genotype correlation has yet been published for JATD. The nearly complete lack of retinal and renal disease in our *DYNC2H1* JATD patients is in striking contrast to an overall high prevalence of childhood end stage renal disease and retinopathy that we and others have found in JATD and other patients who carry biallelic *IFT140* mutations.^{9 12}

Although many ciliary and especially IFT genes are widely expressed throughout the mammalian organism, and primary cilia are present on nearly every cell throughout the human body, ciliopathy phenotypes often seem to be restricted to certain tissues.^{6 64 65} The reason for this remains unclear, but it can be speculated that cell signalling pathways affected by mutations in certain ciliary genes do not have an essential function in every tissue; for example, hedgehog signalling may only cause a visible phenotype in tissues most sensitive for pathway disturbance, possibly in a time-dependent manner, such as during skeletal development. Another hypothesis could be that functionally redundant proteins can compensate for each other's loss in certain tissues.⁶⁶

Our findings have important implications for clinical diagnostics, placing *DYNC2H1* in a separate category from other genes encoding IFT-related proteins, in which mutations are frequently found to be associated with kidney disease and retinal degeneration.^{6 14 65} However, a striking variability of thoracic involvement between different *DYNC2H1* patients and even between siblings with identical *DYNC2H1* genotype was observed in this study. Thus, the rib length thoracic phenotype in *DYNC2H1*-associated JATD and therefore survival chances in infancy are difficult to predict, even with the knowledge of the underlying genotype. This presents a problem in a genetic counselling setting, for example, in cases of prenatal diagnosis for *DYNC2H1* genotypes. At the moment, we can only speculate on the causes of this variability which could be due to other genetic factors such as modifier genes/mutational load,^{11 42 67} or the involvement of epigenetic, environmental and/or stochastic effects. In a similar vein, the p.R330C mutation seems to cause SRPS type II²⁴ as well as JATD without polydactyly, suggesting the polydactyly phenotype does not solely depend on this mutation but might be influenced by modifier genes or epigenetic/non-genetic factors.

Most of the mutations we identified are private and they occur across the entire *DYNC2H1* gene. There is even a striking lack of common alleles despite 5/19 families being consanguineous, three being of common Turkish origin. This implies that all 90 exons of *DYNC2H1* would need to be screened in a clinical genetics diagnosis context. Depending on the screening method and the patient's ethnic origin, a preliminary exclusion of the 'European' mutations p.D3015G, p.R330C, p.I1240T and p.E436* and a focus on the exons that encode the identified functional protein domains would likely be desirable.

In summary, this large WES screen reveals *DYNC2H1* mutations as a frequent cause of JATD, affecting about a third of all families. The mutation spectrum is enriched to *DYNC2H1* functional domains, with a few recurrent alleles, and this information can help to target future genetic screening. The *DYNC2H1*-related phenotype does not appear to arise in the context of

biallelic null-effect mutations, and is predominantly thoracic without extra-skeletal features. Immunostaining for cilia and IFT components in patient fibroblasts presents a potentially useful readout for making a 'skeletal ciliopathy' diagnosis and can provide a tool to functionally evaluate the significance of mutations in retrograde IFT genes. Together, these findings can help to guide clinical diagnostic and genetic counselling decisions in JATD.

Author affiliations

¹Molecular Medicine Unit, Birth Defects Research Centre, University College London (UCL) Institute of Child Health, London, UK

²Department of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands

³Nijmegen Centre for Molecular Life Sciences, Radboud University, Nijmegen, The Netherlands

⁴Institute for Genetic and Metabolic Disease, Radboud University, Nijmegen, The Netherlands

⁵Department of Physiology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands

⁶School of Veterinary Medicine and Science, University of Nottingham, Nottingham, Leicestershire, UK

⁷The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK

⁸Department of Paediatrics, Radboud University Medical Centre, Nijmegen, The Netherlands

⁹Department of Genetics, Environment and Evolution, UCL Genetics Institute (UGI), University College London, London, UK

¹⁰Division of Pediatric Genetics, Center for Pediatrics and Adolescent Medicine, University Hospital Freiburg, Freiburg, Germany

¹¹Department of Epidemiology, Biostatistics and HTA, Radboud University Medical Centre, Nijmegen, The Netherlands

¹²Nijmegen Centre for Evidence Based Practice, Radboud University, Nijmegen, The Netherlands

¹³Department of Pediatrics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

¹⁴Department of Medical Genetics, Institute of Mother and Child, Warsaw, Poland

¹⁵Department of Pediatric Genetics, Marmara University Hospital, Istanbul, Turkey

¹⁶Department of Clinical Genetics, Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands

¹⁷Institute for Medical Genetics and Human Genetics, University Hospital Charité, Berlin, Germany

¹⁸Laboratory for Genetics of Human Development, Department of Human Genetics, KU Leuven University, Leuven, Belgium

¹⁹Department of Clinical Genetics, St. Michael's Hospital, Bristol, UK

²⁰Faculty of Medicine, University of Southampton and Essex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK

²¹Department of Medical Genetics, University Medical Centre Utrecht, Utrecht, The Netherlands

²²Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

²³Istanbul Medical Faculty, Medical Genetics Department, Istanbul University, Istanbul, Turkey

²⁴uk10k.org.uk

Acknowledgements We thank the patients and their families for their participation in the study, as well as the participating physicians. We thank all the participants of the UK10K RARE group, as listed in the online supplementary data file, that is part of the UK10K Consortium (uk10k.org.uk) in particular Matthew Hurles and Saeed Al Turki. We thank N Canham, N Crama, C Marcelis and Professor B Hamel for their clinical input into this project, J de Ligt for bioinformatics assistance and S van der Velde-Visser and M Kipping-Geertsema for excellent technical assistance. The IFT57 and IFT88 antibodies were a generous gift from G Pazour.

Contributors MS, HHA, NVAMK, RR and HMM designed the study and wrote the manuscript. HHA, NVAMK, RR, MS, PJS, PLB and HMM supervised experiments. HHA, EMHFB, ZY, MMO, DA, LD, AH, CG, JAV, NR and E-JK performed whole exome analysis, mutational analyses and other experimental data. RDE performed protein modelling, VP performed copy number variant analysis and both contributed to writing the manuscript. JS and UK10K generated the whole exome sequencing data for UCL patients. AH and CG generated whole sequencing data for Nijmegen patients. Patient clinical ascertainment, clinical data and images were provided by AS-F, AK-K, NEV, MCvM, LG-N, KD, SS, DW, J-BLY, EF, EL, RCMH and HK.

Funding This research was funded by an Action Medical Research UK clinical training fellowship awarded to MS (RTF1411); the Dutch Kidney Foundation

(IP11.58 and KJPB09.009) to HHA; the European Community's Seventh Framework Programme FP7/2009, under grant agreement no. 241955 SYSCILIA, to PLB and RR; a grant from the Netherlands Organisation for Scientific Research (NWO Vidi-91786396) to RR; Newlife Foundation to HMM (10-11/15). DA is funded by Action Medical Research and The Henry Smith Charity (SP4534). Funding for UK10K was provided by the Wellcome Trust under award WT091310.

Competing interests None.

Data sharing statement The authors will share data sets on request.

Patient consent Obtained.

Ethics approval Ethical review boards of the University of Nijmegen and the Institute of Child Health/Great Ormond Street NHS Hospital Trust.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

- Jeune M, Beraud C, Carron R. Asphyxiating thoracic dystrophy with familial characteristics. *Arch Fr Pediatr* 1955;12:886–91.
- Oberklaid F, Danks DM, Mayne V, Campbell P. Asphyxiating thoracic dysplasia. Clinical, radiological, and pathological information on 10 patients. *Arch Dis Child* 1977;52:758–65.
- Herdman RC, Langer LO. The thoracic asphyxiating dystrophy and renal disease. *Am J Dis Child* 1968;116:192–201.
- Allen AW Jr, Moon JB, Hovland KR, Minckler DS. Ocular findings in thoracic-pelvic-phalangeal dystrophy. *Arch Ophthalmol* 1979;97:489–92.
- Bard LA, Bard PA, Owens GW, Hall BD. Retinal involvement in thoracic-pelvic-phalangeal dystrophy. *Arch Ophthalmol* 1978;96:278–81.
- Novarino G, Akizu N, Gleeson JG. Modeling human disease in humans: the ciliopathies. *Cell* 2011;147:70–9.
- Huber C, Cormier-Daire V. Ciliary disorder of the skeleton. *Am J Med Genet C Semin Med Genet* 2012;160:165–74.
- Bredrup C, Saunier S, Oud MM, Fiskerstrand T, Hoischen A, Brackman D, Leh SM, Midtbø M, Filhol E, Bole-Feysot C, Nitschké P, Gilissen C, Haugen OH, Sanders JS, Stolte-Dijkstra I, Mans DA, Steenbergen EJ, Hamel BC, Matignon M, Pfundt R, Jeanpierre C, Boman H, Rødahl E, Veltman JA, Knappskog PM, Knoers NV, Roepman R, Arts HH. Ciliopathies with skeletal anomalies and renal insufficiency due to mutations in the IFT-A gene *WDR19*. *Am J Hum Genet* 2011;89:634–43.
- Perrault I, Saunier S, Hanein S, Filhol E, Bizet AA, Collins F, Salih MA, Gerber S, Delphin N, Bigot K, Orsaud C, Silva E, Baudouin V, Oud MM, Shannon N, Le Merrer M, Roche O, Pietrement C, Goumid J, Baumann C, Bole-Feysot C, Nitschke P, Zahrate M, Beales P, Arts HH, Munnich A, Kaplan J, Antignac C, Cormier-Daire V, Rozet JM. Mainzer-Saldino syndrome is a ciliopathy caused by *IFT140* mutations. *Am J Hum Genet* 2012;90:864–70.
- Beales PL, Bland E, Tobin JL, Bacchelli C, Tuysuz B, Hill J, Rix S, Pearson CG, Kai M, Hartley J, Johnson C, Irving M, Elcioglu N, Winey M, Tada M, Scambler PJ. *IFT80*, which encodes a conserved intraflagellar transport protein, is mutated in Jeune asphyxiating thoracic dystrophy. *Nat Genet* 2007;39:727–9.
- Davis EE, Zhang Q, Liu Q, Diplas BH, Davey LM, Hartley J, Stoetzel C, Szymanska K, Ramaswami G, Logan CV, Muzny DM, Young AC, Wheeler DA, Cruz P, Morgan M, Lewis LR, Cherukuri P, Maskeri B, Hansen NF, Mullikin JC, Blakesley RW, Bouffard GG; NISC Comparative Sequencing Program, Gyapay G, Rieger S, Tönshoff B, Kern I, Soliman NA, Neuhaus TJ, Swoboda KJ, Kayserili H, Gallagher TE, Lewis RA, Bergmann C, Otto EA, Saunier S, Scambler PJ, Beales PL, Gleeson JG, Maher ER, Attié-Bitach T, Dollfus H, Johnson CA, Green ED, Gibbs RA, Hildebrandt F, Pierce EA, Katsanis N. *TTC21B* contributes both causal and modifying alleles across the ciliopathy spectrum. *Nat Genet* 2011;43:189–96.
- Schmidts M, Frank V, Eisenberger T, al Turki S, Antony D, Rix S, Decker C, Bachmann N, Bald M, Vinke T, Toenshoff B, Di Donato N, Neuhann T, Hartley JL, Maher ER, Bogdanović R, Peco-Antić A, Mache C, Hurles ME, UK10K, Bolz HJ, Pazour GJ, Beales PL, Scambler PJ, Mitchison HM, Bergmann C. Combined NGS approaches identify mutations in the intraflagellar transport gene *IFT140* in skeletal ciliopathies with early progressive kidney disease. *Hum Mut* In press. 15 Feb 2013 11:30AM EST | doi:10.1002/humu.22294
- Dagoneau N, Goulet M, Genevieve D, Sznajder Y, Martinovic J, Smithson S, Huber C, Baujat G, Flori E, Tecco L, Cavalcanti D, Delezoide AL, Serre V, Le Merrer M, Munnich A, Cormier-Daire V. *DYNC2H1* mutations cause asphyxiating thoracic dystrophy and short rib-polydactyly syndrome, type III. *Am J Hum Genet* 2009;84:706–11.
- Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. *N Engl J Med* 2011;364:1533–43.

- 15 Scholey JM. Intraflagellar transport motors in cilia: moving along the cell's antenna. *J Cell Biol* 2008;180:23–9.
- 16 Rosenbaum JL, Witman GB. Intraflagellar transport. *Nat Rev Mol Cell Biol* 2002;3:813–25.
- 17 Taschner M, Bhogaraju S, Lorentzen E. Architecture and function of IFT complex proteins in ciliogenesis. *Differentiation* 2012;83:512–22.
- 18 Cole DG, Snell WJ. SnapShot: intraflagellar transport. *Cell* 2009;137:784.
- 19 Piperno G, Siuda E, Henderson S, Segil M, Vaananen H, Sassaroli M. Distinct mutants of retrograde intraflagellar transport (IFT) share similar morphological and molecular defects. *J Cell Biol* 1998;143:1591–601.
- 20 Walczak-Szulpa J, Eggenschwiler J, Osborn D, Brown DA, Emma F, Klingenberg C, Hennekam RC, Torre G, Garshasbi M, Tzschach A, Szczepanska M, Krawczynski M, Zachwieja J, Zwolinska D, Beales PL, Ropers HH, Latos-Bielenska A, Kuss AW. Cranioectodermal Dysplasia, Sensenbrenner syndrome, is a ciliopathy caused by mutations in the *IFT122* gene. *Am J Hum Genet* 2010;86:949–56.
- 21 Arts HH, Bongers EM, Mans DA, van Beersum SE, Oud MM, Bolat E, Spruijt L, Cornelissen EA, Schuurs-Hoeijmakers JH, de Leeuw N, Cormier-Daire V, Brunner HG, Knoers NV, Roepman R. *C14ORF179* encoding IFT43 is mutated in Sensenbrenner syndrome. *J Med Genet* 2011;48:390–5.
- 22 Gillissen C, Arts HH, Hoischen A, Spruijt L, Mans DA, Arts P, van Lie B, Steehouwer M, van Reeuwijk J, Kant SG, Roepman R, Knoers NV, Veltman JA, Brunner HG. Exome sequencing identifies *WDR35* variants involved in Sensenbrenner syndrome. *Am J Hum Genet* 2010;87:418–23.
- 23 Cavalcanti DP, Huber C, Sang KH, Baujat G, Collins F, Delezoide AL, Dagoneau N, Le Merrer M, Martinovic J, Mello MF, Vekemans M, Munnich A, Cormier-Daire V. Mutation in *IFT80* in a fetus with the phenotype of Verma-Naumoff provides molecular evidence for Jeune-Verma-Naumoff dysplasia spectrum. *J Med Genet* 2011;48:88–92.
- 24 El Hokayem J, Huber C, Couve A, Aziza J, Baujat G, Bouvier R, Cavalcanti DP, Collins FA, Cordier MP, Delezoide AL, Gonzales M, Johnson D, Le Merrer M, Levy-Mozziconacci A, Loget P, Martin-Coignard D, Martinovic J, Mortier GR, Perez MJ, Roume J, Scarano G, Munnich A, Cormier-Daire V. *NEK1* and *DYNC2H1* are both involved in short rib polydactyly Majewski type but not in Beemer Langer cases. *J Med Genet* 2012;49:227–33.
- 25 Thiel C, Kessler K, Giessl A, Dimmler A, Shalev SA, von der Haar S, Zenker M, Zahnleiter D, Stöss H, Beinder E, Abou Jamra R, Ekici AB, Schröder-Kress N, Aigner T, Kirchner T, Reis A, Brandstätter JH. *NEK1* mutations cause short-rib polydactyly syndrome type majewski. *Am J Hum Genet* 2011;88:106–14.
- 26 Merrill AE, Merriman B, Farrington-Rock C, Camacho N, Sebald ET, Funari VA, Schibler MJ, Firestein MH, Cohn ZA, Priore MA, Thompson AK, Rimoin DL, Nelson SF, Cohn DH, Krakow D. Ciliary abnormalities due to defects in the retrograde transport protein *DYNC2H1* in short-rib polydactyly syndrome. *Am J Hum Genet* 2009;84:542–9.
- 27 Gibbons BH, Asai DJ, Tang WJ, Hays TS, Gibbons IR. Phylogeny and expression of axonemal and cytoplasmic dynein genes in sea urchins. *Mol Biol Cell* 1994;5:57–70.
- 28 Pfister KK, Shah PR, Hummerich H, Russ A, Cotton J, Annuar AA, King SM, Fisher EM. Genetic analysis of the cytoplasmic dynein subunit families. *PLoS Genet* 2006;2:e1.
- 29 Pazour GJ, Dickert BL, Witman GB. The DHC1b (DHC2) isoform of cytoplasmic dynein is required for flagellar assembly. *J Cell Biol* 1999;144:473–81.
- 30 Carter AP, Cho C, Jin L, Vale RD. Crystal structure of the dynein motor domain. *Science* 2011;331:1159–65.
- 31 Carter AP, Vale RD. Communication between the AAA+ ring and microtubule-binding domain of dynein. *Biochem Cell Biol* 2010;88:15–21.
- 32 Kon T, Oyama T, Shimo-Kon R, Imamura K, Shima T, Sutoh K, Kurisu G. The 2.8 Å crystal structure of the dynein motor domain. *Nature* 2012;484:345–50.
- 33 Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. *Bioinformatics* 2006;22:195–201.
- 34 Knowles MR, Leigh MW, Carson JL, Davis SD, Dell SD, Ferkol TW, Olivier KN, Sagel SD, Rosenfeld M, Burns KA, Minnix SL, Armstrong MC, Lori A, Hazucha MJ, Loges NT, Olbrich H, Becker-Heck A, Schmidts M, Werner C, Omran H, Zariwala MA. Mutations of *DNAH11* in patients with primary ciliary dyskinesia with normal ciliary ultrastructure. *Thorax* 2012;67:433–41.
- 35 Hornef N, Olbrich H, Horvath J, Zariwala MA, Fliegauf M, Loges NT, Wildhaber J, Noone PG, Kennedy M, Antonarakis SE, Blouin JL, Bartoloni L, Nüsslein T, Ahrens P, Griese M, Kuhl H, Sudbrak R, Knowles MR, Reinhardt R, Omran H. *DNAH5* mutations are a common cause of primary ciliary dyskinesia with outer dynein arm defects. *Am J Respir Crit Care Med* 2006;174:120–6.
- 36 Harms MB, Ori-McKenney KM, Scoto M, Tuck EP, Bell S, Ma D, Masi S, Allred P, Al-Lozi M, Reilly MM, Miller LJ, Jani-Acsadi A, Pestronk A, Shy ME, Muntoni F, Vallee RB, Baloh RH. Mutations in the tail domain of *DYNC1H1* cause dominant spinal muscular atrophy. *Neurology* 2012;78:1714–20.
- 37 Weedon MN, Hastings R, Caswell R, Xie W, Paszkiewicz K, Antoniadis T, Williams M, King C, Greenhalgh L, Newbury-Ecob R, Ellard S. Exome sequencing identifies a *DYNC1H1* mutation in a large pedigree with dominant axonal Charcot-Marie-Tooth disease. *Am J Hum Genet* 2011;89:308–12.
- 38 Willemsen MH, Vissers LE, Willemsen MA, van Bon BW, Kroes T, de Ligt J, de Vries BB, Schoots J, Lugtenberg D, Hamel BC, van Bokhoven H, Brunner HG, Veltman JA, Kleefstra T. Mutations in *DYNC1H1* cause severe intellectual disability with neuronal migration defects. *J Med Genet* 2012;49:179–83.
- 39 Tsurusaki Y, Saitoh S, Tomizawa K, Sudo A, Asahina N, Shiraiishi H, Ito JJ, Tanaka H, Doi H, Saitou H, Miyake N, Matsumoto N. A *DYNC1H1* mutation causes a dominant spinal muscular atrophy with lower extremity predominance. *Neurogenetics* 2012;13:327–32.
- 40 Signor D, Wedaman KP, Orozco JT, Dwyer ND, Bargmann CI, Rose LS, Scholey JM. Role of a class DHC1b dynein in retrograde transport of IFT motors and IFT raft particles along cilia, but not dendrites, in chemosensory neurons of living *Caenorhabditis elegans*. *J Cell Biol* 1999;147:519–30.
- 41 Ocbina PJ, Anderson KV. Intraflagellar transport, cilia, and mammalian Hedgehog signaling: analysis in mouse embryonic fibroblasts. *Dev Dyn* 2008;237:2030–8.
- 42 Ocbina PJ, Eggenschwiler JT, Moskowitz I, Anderson KV. Complex interactions between genes controlling trafficking in primary cilia. *Nat Genet* 2011;43:547–53.
- 43 Palmer KJ, MacCarthy-Morrogh L, Smyllie N, Stephens DJ. A role for Tctex-1 (*DYNLT1*) in controlling primary cilium length. *Eur J Cell Biol* 2011;90:865–71.
- 44 Porter ME, Bower R, Knott JA, Byrd P, Dentler W. Cytoplasmic dynein heavy chain 1b is required for flagellar assembly in *Chlamydomonas*. *Mol Biol Cell* 1999;10:693–712.
- 45 Schafer JC, Haycraft CJ, Thomas JH, Yoder BK, Swoboda P. *XBX-1* encodes a dynein light intermediate chain required for retrograde intraflagellar transport and cilia assembly in *Caenorhabditis elegans*. *Mol Biol Cell* 2003;14:2057–70.
- 46 Hou Y, Pazour GJ, Witman GB. A dynein light intermediate chain, D1bLIC, is required for retrograde intraflagellar transport. *Mol Biol Cell* 2004;15:4382–94.
- 47 Grissom PM, Vaisberg EA, McIntosh JR. Identification of a novel light intermediate chain (D2LIC) for mammalian cytoplasmic dynein 2. *Mol Biol Cell* 2002;13:817–29.
- 48 Perrone CA, Tritschler D, Taulman P, Bower R, Yoder BK, Porter ME. A novel dynein light intermediate chain colocalizes with the retrograde motor for intraflagellar transport at sites of axoneme assembly in chlamydomonas and mammalian cells. *Mol Biol Cell* 2003;14:2041–56.
- 49 Rompolas P, Pedersen LB, Patel-King RS, King SM. *Chlamydomonas* FAP133 is a dynein intermediate chain associated with the retrograde intraflagellar transport motor. *J Cell Sci* 2007;120:3653–65.
- 50 Pazour GJ, Wilkerson CG, Witman GB. A dynein light chain is essential for the retrograde particle movement of intraflagellar transport (IFT). *J Cell Biol* 1998;141:979–92.
- 51 Li A, Saito M, Chuang JZ, Tseng YY, Dedesma C, Tomizawa K, Kaitsuka T, Sung CH. Ciliary transition zone activation of phosphorylated Tctex-1 controls ciliary resorption, S-phase entry and fate of neural progenitors. *Nat Cell Biol* 2011;13:402–11.
- 52 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007;81:559–75.
- 53 Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. *Cancer Res* 2005;65:6071–9.
- 54 Plagnol V, Curtis J, Epstein M, Mok KSE, Grigoriadou S, Wood NW, Hambleton S, Burns SO, Thrasher A, Kumararatne D, Doffinger R, Nejentsev S. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. *Bioinformatics* 2012;28:2747–54.
- 55 de Vries J, Yntema JL, van Die CE, Crama N, Cornelissen EA, Hamel BC. Jeune syndrome: description of 13 cases and a proposal for follow-up protocol. *Eur J Pediatr* 2010;169:77–88.
- 56 Olbrich H, Schmidts M, Werner C, Onoufriadis A, Loges NT, Raidt J, Banki NF, Shoemark A, Burgoyne T, Al Turki S, Hurles ME, UK10K, Köhler G, Schroeder J, Nürnberg G, Nürnberg P, Chung EMK, Reinhardt R, Marthin JK, Nielsen KG, Mitchison HM, Omran H. Recessive *HYDIN* mutations cause Primary Ciliary Dyskinesia without randomization of left/right body asymmetry. *Am J Hum Genet* 2012;91:672–84.
- 57 Arts HH, Doherty D, van Beersum SE, Parisi MA, Letteboer SJ, Gorden NT, Peters TA, Märker T, Voeselek K, Kartono A, Ozyurek H, Farin FM, Kroes HY, Wolfrum U, Brunner HG, Cremers FP, Glass IA, Knoers NV, Roepman R. Mutations in the gene encoding the basal body protein RFGRIIP1L, a nephrocystin-4 interactor, cause Joubert syndrome. *Nat Genet* 2007;39:882–8.
- 58 Olbrich H, Haffner K, Kispert A, Volkel A, Volz A, Sasmaz G, Reinhardt R, Hennig S, Lehrach H, Konietzko N, Zariwala M, Noone PG, Knowles M, Mitchison HM, Meeks M, Chung EM, Hildebrandt F, Sudbrak R, Omran H. Mutations in *DNAH5* cause primary ciliary dyskinesia and randomization of left-right asymmetry. *Nat Genet* 2002;30:143–4.
- 59 Faily M, Bartoloni L, Letourneau A, Munoz A, Falconnet E, Rossier C, de Santi MM, Santamaria F, Sacco O, DeLozier-Blanchet CD, Lazor R, Blouin JL. Mutations in *DNAH5* account for only 15% of a non-preselected cohort of patients with primary ciliary dyskinesia. *J Med Genet* 2009;46:281–6.

- 60 Djakow J, Svobodova T, Hrach K, Uhlik J, Cinek O, Pohunek P. Effectiveness of sequencing selected exons of DNAH5 and DNAI1 in diagnosis of primary ciliary dyskinesia. *Pediatr Pulmonol* 2012;47:864–75.
- 61 Kon T, Nishiura M, Ohkura R, Toyoshima YY, Sutoh K. Distinct functions of nucleotide-binding/hydrolysis sites in the four AAA modules of cytoplasmic dynein. *Biochemistry* 2004;43:11266–74.
- 62 Burgess SA, Walker ML, Sakakibara H, Knight PJ, Oiwa K. Dynein structure and power stroke. *Nature* 2003;421:715–18.
- 63 Schmidt H, Gleave ES, Carter AP. Insights into dynein motor domain function from a 3.3-Å crystal structure. *Nat Struct Mol Biol* 2012;19:492–7. S1.
- 64 Rix S, Calmont A, Scambler PJ, Beales PL. An Ift80 mouse model of short rib polydactyly syndromes shows defects in hedgehog signalling without loss or malformation of cilia. *Hum Mol Genet* 2011;20:1306–14.
- 65 Waters AM, Beales PL. Ciliopathies: an expanding disease spectrum. *Pediatr Nephrol* 2011;26:1039–56.
- 66 Hao L, Efimenko E, Swoboda P, Scholey JM. The retrograde IFT machinery of *C. elegans* cilia: two IFT dynein complexes? *PLoS One* 2011;6:e20995.
- 67 Lee S, Weatherbee SD. Synergistic interaction between ciliary genes reflects the importance of mutational load in ciliopathies. *J Am Soc Nephrol* 2010;21:724–6.



Exome sequencing identifies *DYNC2H1* mutations as a common cause of asphyxiating thoracic dystrophy (Jeune syndrome) without major polydactyly, renal or retinal involvement

Miriam Schmidts, Heleen H Arts, Ernie M H F Bongers, Zhimin Yap, Machteld M Oud, Dinu Antony, Lonneke Duijkers, Richard D Emes, Jim Stalker, Jan-Bart L Yntema, Vincent Plagnol, Alexander Hoischen, Christian Gilissen, Elisabeth Forsythe, Ekkehart Lausch, Joris A Veltman, Nel Roeleveld, Andrea Superti-Furga, Anna Kutkowska-Kazmierczak, Erik-Jan Kamsteeg, Nursel Elçioglu, Merel C van Maarle, Luitgard M Graul-Neumann, Koenraad Devriendt, Sarah F Smithson, Diana Wellesley, Nienke E Verbeek, Raoul C M Hennekam, Hulya Kayserili, Peter J Scambler, Philip L Beales, Nine VAM Knoers, Ronald Roepman and Hannah M Mitchison

J Med Genet 2013 50: 309-323 originally published online March 1, 2013
doi: 10.1136/jmedgenet-2012-101284

Updated information and services can be found at:
<http://jmg.bmj.com/content/50/5/309>

These include:

Supplementary Material

Supplementary material can be found at:
<http://jmg.bmj.com/content/suppl/2013/02/27/jmedgenet-2012-101284.DC1.html>

References

This article cites 66 articles, 25 of which you can access for free at:
<http://jmg.bmj.com/content/50/5/309#BIBL>

Open Access

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: <http://creativecommons.org/licenses/by-nc/3.0/> and <http://creativecommons.org/licenses/by-nc/3.0/legalcode>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Open access](#) (162)
[Molecular genetics](#) (1234)
[Eye Diseases](#) (294)

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>